Trial Profile
Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs LY 2886721 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 09 Aug 2012 Actual end date (July 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.